Under assessment · Notification · Phase 1 · day 3, due 1 Dec 2026
Novotech Aus BidCo Pty Ltd, a subsidiary of Novotech SG Holdings Pty Ltd, proposes to acquire 100% of the shares in Agilex Biolabs Pty Ltd. This share sale unites Novotech, a global clinical research organisation, with Agilex, an Australian specialist bioanalytical services provider, both in clinical trial development. Novotech's controlling shareholders are TPG Inc. affiliated funds.
Novotech Aus BidCo Pty Ltd, a subsidiary of Novotech SG Holdings Pty Ltd (Novotech) proposes to acquire 100% of the shares in Agilex Biolabs Pty Ltd (Agilex). Novotech is a full-service clinical research organisation (CRO) and science advisory company, operating worldwide. In Australia, Novotech provides CRO services offering clinical trial design and management across principally Phases I to III of clinical trial development. Novotech does not have any laboratories in Australia and does not provide any bioanalytical laboratory services from Australia. It operates laboratories in Shanghai and Taipei from which it supplies some offshore laboratory services for clinical trials in Australia. Novotech also has a sample collection and storage facility in North Carolina (USA). Novotech’s controlling shareholders are private investment funds affiliated with TPG Inc (TPG). TPG is a global alternative asset management firm headquartered in the United States with $306 billion of assets under management as at 31 March 2026. Agilex is an Australian specialist bioanalytical services provider supporting non-clinical and clinical drug development programmes across Phases I to III, with Phase I being a core focus. Agilex's services are focused on bioanalysis and specialised sample processing. Agilex has laboratories in Adelaide and Brisbane, with a Sydney facility in development.